A Non-Covalent Peptide-Based Strategy for siRNA Delivery
The development of short-interfering RNA (siRNA) has provided great hope for therapeutic targeting of specific genes responsible for pathological disorders. However, the poor cellular uptake of siRNA together with the low permeability of the cell membrane to negatively charged molecules, remain major obstacles to clinical development. So far there is no universal method for siRNA delivery as they all present several limitations. Several non-viral strategies have been proposed to improve the delivery of synthetic siRNAs in both cultured cells and in vivo. Cell-penetrating peptides (CPPs) or protein transduction domains (PTD) constitute very promising tools for non-invasive cellular import of siRNA and non-covalent CPP/PTD-based strategies have been successfully applied for ex vivo and in vivo delivery of therapeutic siRNA molecules. We recently described a new peptide-based system, CADY, for efficient delivery of siRNA in both primary and suspension cell lines. CADY is a secondary amphiphatic peptide able to form stable non-covalent complexes with siRNA and to improve their cellular uptake independently of the endosomal pathway. This chapter describes easy to handle protocols for the use of the CADY-nanoparticle technology for the delivery of siRNA into both adherent and suspension cell lines. It will also highlight different critical points in the peptide/siRNA complex preparation and transfection protocols, in order to obtain siRNA-associated interfering response at low nanomolar concentration.
Key wordsCell-penetrating peptide Peptide-based non-covalent strategy Amphiphatic peptide Non-endosomal pathway siRNA delivery
This work was supported in part by the Centre National de la Recherche Scientifique (CNRS), by the Agence Nationale de la Recherche (ANR, ANR-06-BLAN-0071-Pepvec4Ther), and by a grant from Panomics Inc. L.C. was supported by a grant from the Ligue de Recherche contre le Cancer (LNCC). We thank M.C. Morris for critical reading of the manuscript and all members of the laboratory for fruitful discussions.
- 15.Moschos, SA., Jones, SW., Perry, MM., Williams, AE., Erjefalt, JS., Turner, JJ., Barnes, PJ., Sproat, BS., Gait, MJ., and Lindsay, MA. (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 18, 1450–1459.CrossRefPubMedGoogle Scholar
- 19.Zeineddine, D., Papadimou, E., Chebli, K., Gineste, M., Liu, J., Grey, C., Thurig, S., Behfar, A., Wallace, VA., Skerjanc, IS., and Puceat, M. (2006) Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev Cell. 11, 535–546.CrossRefPubMedGoogle Scholar
- 23.Kumar, P., Ban, HS., Kim, SS., Wu, H., Pearson, T., Greiner, DL., Laouar, A., Yao, J., Haridas, V., Habiro, K., Yang, YG, Jeong, JH., Lee, KY., Kim, YH., Kim, SW., Peipp, M., Fey, GH., Manjunath, N., Shultz, LD., Lee, SK., and Shankar, P. (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 134, 577–586.CrossRefPubMedGoogle Scholar
- 28.Deshayes, S., Konate, K., Aldrian, G., Heitz, F., and Divita, G. (2010) Interactions of amphipathic CPPs with model membranes. In: Ülo Langel (ed.) Cell-Penetrating Peptides: Methods and Protocol (Methods Mol Biol, 683). Chapter 4, Springer, New York.Google Scholar